Cipla expects margin, RoCE expansion in FY21; ability to supply crucial, says CFO

"In pharma, demand is there, but growth depends more on our ability to supply," Upadhye said in the context of COVID-19 pandemic that#39;s threatening operations. The lockdown had impacted sales of Rs 200 crore for Q4FY20